Browsing Category
24414 posts
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant and clinically meaningful improvement in overall survival benefit for Asian patients with EGFR-mutated non-small cell lung cancer in the Phase 3 MARIPOSA study
SINGAPORE, Dec. 8, 2025 First and only chemotherapy-free combination in the first-line…